LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.25), Zacks reports.
LogicBio Therapeutics Stock Down 1.3%
OTCMKTS:LOGC opened at $15.10 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 1.24 and a current ratio of 1.87. The company has a market cap of $690.54 million, a PE ratio of -20.68 and a beta of 2.11. LogicBio Therapeutics has a 52-week low of $7.05 and a 52-week high of $15.60. The stock has a 50-day simple moving average of $14.76 and a 200 day simple moving average of $10.34.
About LogicBio Therapeutics
LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.
LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.
Read More
- Five stocks we like better than LogicBio Therapeutics
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
